Paris, France
Paris, France

Time filter

Source Type

Median Technologies (Paris:ALMDT), le spécialiste de l’imagerie phénomique, annonce aujourd’hui sa participation à la réunion annuelle de l’Asian Pacific Association for the Study of the Liver (APASL) du 15 au 19 Février au Shanghai International Convention Center, Shanghai, Chine. Du 17 au 19 Février, dates de l’exposition technique, Median Technologies y démontrera sa nouvelle plateforme d’imagerie phénomique iBiopsy™, appliquée au contexte des stéatoses hépatiques non alcooliques sur le stand FURUI / Echosens (stand 116-117). iBiopy™ (Imaging Biomarker Phenotyping System) est une plateforme innovante qui allie les biomarqueurs d’imagerie non-invasifs à la phénomique. Cette combinaison unique de la science et de la technologie est centrale dans le contexte de la médecine prédictive et de la médecine personnalisée car elle donne des indications à la fois pour le développement de nouvelles thérapies et pour la mise en place de stratégies de traitement individualisées. En particulier, iBiopsy™ permet de mesurer la maladie et d’évaluer la réponse au traitement sans recours à des biopsies, qui sont des procédures invasives et coûteuses. Le premier contexte d’utilisation de iBiopsy™ est celui des stéatoses hépatiques non alcooliques (Non Alcoholic Steatohepatitis NASH), dont la prévalence est en forte augmentation en Asie et dans d’autres régions du monde. Median Technologies fera également une présentation « Imaging Phenomics for the Assessment of Progression of NASH », dans le cadre du satellite symposium co-organisé par FURUI et Echosens. Le satellite symposium dont le sujet est les technologies innovantes qui changent l’hépatologie aura lieu le 16 Février de 18h à 19h30. « Nous avons travaillé étroitement avec FURUI depuis leur investissement dans notre société finalisé en décembre dernier et nous sommes enchantés d’avoir été conviés à participer à la réunion annuelle de l’APASL sous leur égide », précise Fredrik Brag, PDG de Median Technologies. « La prévalence des maladies hépatiques augmente dans les pays asiatiques et la première application de notre plateforme iBiopsy™ concerne les stéatoses hépatiques non alcooliques. Nous sommes confiants dans le fait que notre technologie innovante va apporter de nouvelles solutions pour mieux évaluer ces pathologies hépatiques et va contribuer à l’émergence de nouvelles thérapies pour les patients qui en sont atteints. » A propos de Median Technologies : Median Technologies fournit des solutions et des services d’imagerie innovants afin de faire progresser les soins de santé pour tous. Nous exploitons la puissance de l’imagerie phénomique pour contribuer à l’émergence de nouvelles thérapies et stratégies de traitement pour les patients. Nos solutions, LMS pour la gestion des lésions et notre plateforme d’imagerie phénomique iBiopsy™ alliées à l’expertise de nos équipes contribuent à la découverte de nouveaux médicaments et de nouveaux outils de diagnostic, afin de surveiller les maladies et d’évaluer la réponse des patients à leur thérapie. Median Technologies aide les sociétés biopharmaceutiques ainsi que les professionnels de santé à apporter de nouveaux traitements aux patients qui en ont besoin, de façon plus précise et plus rapide, dans une optique de réduction globale de coûts des soins. Ainsi, nous contribuons à un monde en meilleure santé.


Median Technologies (Paris:ALMDT), the Imaging Phenomics™ Company, announced today that it will participate in the Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL), February 15-19 at the Shanghai International Convention Center, Shanghai, China (exhibition dates: February, 17-19). The company will demonstrate its new Imaging Phenomics™ platform iBiopsy™ applied to the assessment of Nonalcoholic Steatohepatitis (NASH) at FURUI/Echosens booth #116-117. iBiopsy™, or Imaging Biomarker Phenotyping System, is a groundbreaking imaging platform that combines noninvasive image biomarkers with phenomics. This unique combination of science and technology is at the very core of precision and predictive medicine because it can provide insights into development of novel therapies and individualized treatment strategies. Remarkably, iBiopsy™ can measure disease and treatment response without an invasive and costly biopsy. The initial application of iBiopsy™ is for Nonalcoholic Fatty Liver Diseases including NASH, which are dramatically increasing in prevalence in the Asia Pacific and other parts of the world. Median Technologies will also present during the FURUI/Echosens joint satellite symposium “Innovative Technologies change hepatology”. The satellite symposium will take place February 16, from 18:00 to 19:30. Median’s presentation topic is “Imaging Phenomics for the Assessment of Progression of NASH.” “We have been working very closely with FURUI since their investment into Median Technologies completed in December 2016 and are very pleased to have been invited to participate in the Annual Meeting of APASL under their aegis”, said Fredrik Brag, CEO of Median Technologies. “Liver diseases are rapidly increasing in prevalence in Asian countries and our iBiopsy™ platform’s first application is for NASH. We are confident that this groundbreaking technology will bring new insights to better assess these liver diseases and will contribute to the emergence of new therapies for liver patients in need.” APASL is one of the leading associations in the world focused on investigation and treatment of liver diseases. It is the largest scientific body dedicated to advancing improved treatment methods for millions of liver patients in the Asia Pacific Region. About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics™ to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and iBiopsy™ for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median Technologies has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017. More information: www.mediantechnologies.com .


A device for measuring an ultrasonic or biomechanical parameter of a viscoelastic medium, includes an ultrasound transducer; at least one vibrator having a fixed part and a mobile part, the ultrasound transducer being secured to the mobile part of the at least one vibrator; at least one adhesive element secured to the vibrator, the adhesive element being configured to be fixed adhesively to a surface facing it belonging to the viscoelastic medium and to keep the emission and reception face of the ultrasound transducer facing the surface.


A method for measuring at least one property of biological tissue, including: positioning an ultrasonic transducer opposite the biological tissue to be measured; generating an ultrasonic signal within the biological tissue; acquiring at least one ultrasonic signal reflected by the biological tissue; determining at least one parameter of the biological tissue using the acquisition of the ultrasonic signal reflected by the biological tissue, the at least one parameter being representative of the biological tissue; comparing the at least one parameter of the biological tissue with at least one reference parameter of a target biological tissue so as to confirm the hypothesis of the presence of the target biological tissue opposite the ultrasonic transducer; and determining at least one property of the biological tissue on the basis of the result of the comparison. The method can be directly used in the field of humans or animals.


Patent
Echosens | Date: 2016-11-23

An aspect of the invention relates generally to an interchangeable tip (1) for ultrasound probe housing (20) comprising:- At least one ultrasound transducer (2) constructed and configured to emit and receive ultrasound signals,- At least one electrical contact (4) of tip, each electrical contact (4) of tip being constructed and configured to cooperate with an electrical connector (5),- A tip connector (11) constructed and configured to secure the interchangeable tip (1) with an ultrasound probe housing (20).


A method for determining, in real time, the probability that target biological tissue is opposite an ultrasonic transducer, the method including: transmitting, via an ultrasonic transducer, an ultrasonic signal into biological tissue; the ultrasonic transducer receiving the transmitted ultrasonic signal which has been backscattered by the biological tissue; calculating at least two instantaneous parameters of the backscattered ultrasonic signal; calculating a predictive value of the presence of an acoustic signature of target biological tissue, the predictive value being calculated via a statistical law using the at least two calculated instantaneous parameters; estimating the probability that the target biological tissue is opposite the ultrasonic transducer, the estimation depending on the calculated predictive value and/or on at least one strength condition based on at least one of the two calculated instantaneous parameters.


Patent
Echosens | Date: 2014-02-19

A multipulse elastography method for the quantitative measurement of at least one mechanical property of a viscoelastic medium having an ultrasonic signal after ultrasonic illumination, the method including defining characteristics of at least two mechanical pulses; generating the at least two mechanical pulses for which characteristics are defined in a viscoelastic medium; monitoring a propagation of at least two shear waves generated by the at least two mechanical pulses using acquisition and emission of ultrasonic signals, in the viscoelastic medium, and calculating at least one mechanical property of said viscoelastic medium using said acquisitions of said ultrasonic signals.


Trademark
Echosens | Date: 2016-07-18

Software used in medical apparatus and instruments for use in measuring, quantifying and assessing liver health. Medical apparatus and instruments for use in measuring, quantifying and assessing liver health.


A non-invasive system for calculating a human or animal score, the system including a measurement slave device constructed and arranged to carry out measurements of biological parameters; a measure slave device constructed and arranged to carry out measurements of physical parameters; a master device constructed and arranged to collect the biological and physical parameters and calculate the human or animal score, the score including biological and physical parameters.

Loading Echosens collaborators
Loading Echosens collaborators